Roche announces that it has entered into a definitive agreement to acquire certain parts of the LumiraDx group related to its innovative point-of-care technology. Following completion, expected by mid-2024, the acquired entities will be integrated into Roche Diagnostics.

The acquired solution, combining multiple diagnostic modalities on a single platform, will complement the Swiss group's portfolio in clinical chemistry, immunochemistry, coagulation and obesity, as well as in multiple disease areas.

LumiraDx's technology integrates multiple point-of-care tests into a single, easy-to-use instrument, bringing more affordable and accessible testing to patients worldwide", says Roche.

The transaction is subject to certain conditions, including regulatory approvals. Under the agreed terms, Roche will pay a purchase price of $295 million and make an additional payment of up to $55 million.

Copyright (c) 2024 CercleFinance.com. All rights reserved.